[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-stage-iv-without-egfralk-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-stage-iv-without-egfralk-mutation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100589206","phase-2-tracking-t-cell-responses-to-evaluate-pembrolizumab-effectiveness-in-advanced-non-small-cell-lung-cancer-100589206",false,"NCT06951399","Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-Small Lung Cancer","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of NSCLC adenocarcinoma stage IV or unresectable stage III.\n* Have measurable disease based on RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Aberration in one or more of molecular drivers.\n* Has received prior systemic anti-cancer therapy prior to allocation.\n* Known active CNS metastases and\u002For carcinomatous meningitis.\n* Known additional malignancy.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study includes patients with advanced non-small cell lung cancer (NSCLC) - either unresectable stage III or stage IV adenocarcinoma without actionable driver mutations - who are treated with pembrolizumab in combination with platinum-based doublet chemotherapy, irrespective of PD-L1 expression levels.\n\nThe primary objective is to assess treatment response through integration of serial T-cell receptor (TCR) repertoire sequencing (Rep-seq), capturing longitudinal changes in T-cell clonality and diversity. These immune dynamics will be correlated with radiographic response assessed by RECIST 1.1, with the aim of improving the accuracy of response classification, including differentiation between progression, pseudo-progression, and hyperprogression.\n\nAdditionally, circulating tumor DNA (ctDNA) levels will be measured longitudinally (pre-treatment and during treatment) to evaluate their potential as a complementary biomarker of disease burden and treatment efficacy in the context of chemo-immunotherapy.",[26,27,28],"NSCLC (Advanced Non-small Cell Lung Cancer)","NSCLC Stage IV Without EGFR\u002FALK Mutation","NSCLC Adenocarcinoma",[30],"metastatic NSCLC adenocarcinoma first-line pembrolizumab","NOT_YET_RECRUITING","2025-07-21",{"date":34,"type":35},"2025-07-22","ACTUAL",{"date":37,"type":20},"2025-09-01",{"date":39,"type":20},"2028-04-30",{"name":41,"class":42},"Rabin Medical Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100588921","phase-2-a-study-on-exploring-the-abscopal-effect-induced-by-different-radioimmunotherapy-combination-patterns-in-the-treatment-of-non-small-cell-lung-cancer-with-multiple-metastases-100588921","NCT06947694","A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","A Prospective, Multicenter, Umbrella Design Clinical Study on the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","Inclusion Criteria:\n\n* Patient must meet all of the following inclusion criteria to be enrolled in this study:\n\n  1. Non-small cell lung cancer diagnosed initially through pathological histology.\n  2. There are 3-6 metastatic lesions.\n  3. No brain metastasis or the lesions are stable.\n  4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names).\n  5. ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months.\n  6. Aged between 18 and 75 years old.\n  7. Evaluated by PET-CT (including FDG and FMISO, not mandatory).\n  8. No contraindications for immunotherapy and radiotherapy.\n  9. The informed consent form has been signed.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria are not eligible for enrollment in this study:\n\n  1. Those with severe dysfunction of vital organs (heart, liver, kidney).\n  2. Those accompanied by other malignant tumors.\n  3. Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months.\n  4. Those with a history of mental illness.\n  5. And other situations in which the researchers deem it inappropriate for the subjects to participate in the study.","75 Years",{"count":53,"type":20},427,[23],"It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. The main objective is to find the optimal organ combination and the best radioimmunotherapy combination pattern.",[27],"RECRUITING","2025-07-16",{"date":34,"type":35},{"date":61,"type":35},"2025-07-02",{"date":63,"type":20},"2027-12-31",{"name":65,"class":42},"Xinqiao Hospital of Chongqing",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":84,"locationsCount":43},"100589394","phase-2-study-on-the-optimal-combination-pattern-of-the-combined-treatment-of-radiotherapy-and-immunotherapy-for-the-abscopal-effect-in-non-small-cell-lung-cancer-nsclc-with-multiple-metastases-100589394","NCT06953843","Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases","An Umbrella Trial of Combining Different Radiotherapy Fractionation Patterns With Immunotherapy for Multiple Metastases of Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patient must meet all of the following inclusion criteria to be enrolled in this study:\n\n  1. Non-small cell lung cancer confirmed by pathological histology.\n  2. More than 3 metastatic lesions.\n  3. No brain metastases or stable lesions.\n  4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).\n  5. Performance status (PS) score of 0-1, with an expected survival period of more than 3 months.\n  6. Age between 18 and 75 years old.\n  7. Assessment by PET-CT (including FDG and FMISO, not mandatory).\n  8. No contraindications to immunotherapy and radiotherapy.\n  9. Signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria are not eligible for enrollment in this study:\n\n  1. Those with severe dysfunction of important vital organs (heart, liver, kidney).\n  2. Those accompanied by other malignant tumors.\n  3. Uncontrolled heart diseases or myocardial infarction within the past 6 months.\n  4. Those with a history of mental illness.\n  5. Other situations in which the researcher deems it inappropriate for the subject to participate in the study.",{"count":74,"type":20},366,[23],"This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.",[27],"2025-07-11",{"date":80,"type":35},"2025-07-14",{"date":82,"type":20},"2025-07-09",{"date":63,"type":20},{"name":65,"class":42}]